These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23306954)

  • 1. High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
    Goto S; Tomiya A
    Thromb Haemost; 2013 Feb; 109(2):177-8. PubMed ID: 23306954
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching from prasugrel to clopidogrel: navigating in unknown waters.
    Angiolillo DJ; Rollini F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):166-8. PubMed ID: 23428008
    [No Abstract]   [Full Text] [Related]  

  • 3. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
    Lhermusier T; Voisin S; Murat G; Mejean S; Garcia C; Bataille V; Lipinski MJ; Carrié D; Sié P
    Int J Cardiol; 2014 Jul; 174(3):874-6. PubMed ID: 24820749
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel versus clopidogrel.
    Pasceri V; Patti G; Di Sciascio G
    N Engl J Med; 2008 Mar; 358(12):1298-9; author reply 1299-301. PubMed ID: 18357638
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
    Cornel JH; Ohman EM; Neely B; Clemmensen P; Sritara P; Zamoryakhin D; Armstrong PW; Prabhakaran D; White HD; Fox KA; Gurbel PA; Roe MT;
    Am Heart J; 2014 Jul; 168(1):76-87.e1. PubMed ID: 24952863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial".
    Alexopoulos D; Xanthopoulou I
    Circ Cardiovasc Interv; 2013 Feb; 6(1):e11. PubMed ID: 23424274
    [No Abstract]   [Full Text] [Related]  

  • 13. Toward a therapeutic window for antiplatelet therapy in the elderly.
    Gurbel PA; Ohman EM; Jeong YH; Tantry US
    Eur Heart J; 2012 May; 33(10):1187-9. PubMed ID: 22270540
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
    Enar R
    Turk Kardiyol Dern Ars; 2013 Mar; 41(2):166-71. PubMed ID: 23666308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Twelve or thirty months of dual antiplatelet Therapy after drug-eluting stents. Results of the DAPT trial].
    Liakishev AA
    Kardiologiia; 2015; 55(1):57-8. PubMed ID: 26050492
    [No Abstract]   [Full Text] [Related]  

  • 16. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
    Bernlochner I; Mayer K; Morath T; Braun S; Schulz S; Schömig A; Koch W; Kastrati A; Sibbing D
    Platelets; 2013; 24(6):500-2. PubMed ID: 22916844
    [No Abstract]   [Full Text] [Related]  

  • 19. Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Dec; 78(11):1252-3. PubMed ID: 19069017
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
    Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.